Press release
Neurofibromatoses Type I Pipeline Analysis - Opportunities sales, Revenue, Gross Margin and Forecast to 2018
Neurofibromatoses type I is a genetic condition characterized by the growth of tumours along the nerves in the brain, skin and other parts of the body, and skin pigmentation. Neurofibromatoses is an autosomal dominant disorder which is caused by the mutation in NF1 gene, a tumour suppressor gene, that encodes protein to stop growing and dividing in an uncontrolled manner. The condition usually begins in early childhood, which causes flat patches on the skin that are darker. In later childhood, freckles can be developed in the underarms and groins. The signs and symptoms of neurofibromatoses type I include hypertension, macrocephaly, short stature, skeletal abnormalities, autism spectrum disorder, learning disabilities, and seizures. Universitaire Ziekenhuizen Leuven is in the process of developing lamotrigine as a sodium channel antagonist for the treatment of neurofibromatoses type I. University of Utah is in the process of developing cholecalciferol for the treatment of neurofibromatoses type I. Some of the companies and universities having the pipeline of neurofibromatoses include Universitaire Ziekenhuizen Leuven, Vanderbilt University, and others.Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-type-i-therapeutics-pipeline-analysis/report-sample
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Explore Report at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-type-i-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatoses Type I Pipeline Analysis - Opportunities sales, Revenue, Gross Margin and Forecast to 2018 here
News-ID: 974085 • Views: …
More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of…

Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where…

Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the…

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
More Releases for Neurofibromatoses
Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively …
DelveInsight's, "Neurofibromatoses Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neurofibromatoses pipeline landscape. It covers the Neurofibromatoses pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibromatoses pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in…
From $46.03B in 2024 to $99.23B by 2032: Minimally Invasive Non-Invasive Product …
Market Trend
The Minimally Invasive Non-Invasive Product Service Market is experiencing robust growth driven by technological advancements in medical devices and increasing patient demand for less invasive procedures. There is a notable trend towards integrating digital health solutions, including telemedicine and remote monitoring, to complement minimally invasive techniques, enhancing patient convenience and outcomes. Additionally, the rise of robotic-assisted surgeries and innovative imaging technologies is expanding the scope of non-invasive procedures across…
Neurofibromatosis Therapeutics Pipeline - Key Players Analysis Novartis, AstraZe …
The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.
Browse report sample at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis/report-sample
*Positive clinical trial results propelling the growth of the pipeline therapeutics of the Neurofibromatosis
The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination…
Neurofibromatosis Therapeutics Pipeline Analysis Report 2018: Clinical Trials & …
The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.
Request to get the Sample Report@ https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis/report-sample
Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology…
Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review and Mar …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) pipeline landscape.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196646
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2017,…
Neurofibromatoses Type II Market Analysis- opportunities sales, revenue, Gross M …
ReportBazzar has released its latest research-based report entitled ‘Neurofibromatoses Type II’ market.
This report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Neurofibromatoses Type II market. The report also provides a detailed analysis of key trends and latest technologies, playing a prominent role in the Neurofibromatoses Type II market growth. It takes into account aspects such as drivers,…